196 related articles for article (PubMed ID: 35329897)
1. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
Kawaratani H; Kondo Y; Tatsumi R; Kawabe N; Tanabe N; Sakamaki A; Okumoto K; Uchida Y; Endo K; Kawaguchi T; Oikawa T; Ishizu Y; Hige S; Takami T; Terai S; Ueno Y; Mochida S; Takikawa Y; Torimura T; Matsuura T; Ishigami M; Koike K; Yoshiji H
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329897
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese.
Nishida S; Hamada K; Nishino N; Fukushima D; Koyanagi R; Horikawa Y; Shiwa Y; Saitoh S
World J Hepatol; 2019 Jun; 11(6):531-541. PubMed ID: 31293721
[TBL] [Abstract][Full Text] [Related]
3. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy.
Ishikawa T; Endo S; Imai M; Azumi M; Nozawa Y; Sano T; Iwanaga A; Honma T; Yoshida T
Intern Med; 2020; 59(20):2465-2469. PubMed ID: 33055469
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites.
Yokoyama K; Fukuda H; Yamauchi R; Higashi M; Miyayama T; Higashi T; Uchida Y; Shibata K; Tsuchiya N; Fukunaga A; Umeda K; Takata K; Tanaka T; Shakado S; Sakisaka S; Hirai F
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143954
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients.
Hiramine Y; Uto H; Mawatari S; Kanmura S; Imamura Y; Hiwaki T; Saishoji A; Kakihara A; Maenohara S; Tokushige K; Ido A
Hepatol Res; 2021 Apr; 51(4):445-460. PubMed ID: 33533150
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.
Fujiwara Y; Suzuki K; Yusa K; Eizuka M; Miura M; Watanabe Y; Takahashi H; Takikawa Y
Intern Med; 2021; 60(7):1027-1033. PubMed ID: 33790139
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
Hammd M; Elghezewi A; Abdulhadi A; Alabid A; Alabid A; Badi Y; Kamal I; Hesham Gamal M; Mohamed Fisal K; Mujtaba M; Sherif A; Frandah W
Cureus; 2024 Jan; 16(1):e53341. PubMed ID: 38435950
[TBL] [Abstract][Full Text] [Related]
8. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
Nakai M; Suda G; Ogawa K; Yoshida S; Hosoda S; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Ohara M; Sho T; Morikawa K; Sakamoto N
PLoS One; 2022; 17(7):e0270786. PubMed ID: 35776720
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
Mullen KD; Sanyal AJ; Bass NM; Poordad FF; Sheikh MY; Frederick RT; Bortey E; Forbes WP
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1390-7.e2. PubMed ID: 24365449
[TBL] [Abstract][Full Text] [Related]
11. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan.
Chang C; Huang CH; Tseng HJ; Yang FC; Chien RN
J Pers Med; 2021 May; 11(6):. PubMed ID: 34071787
[TBL] [Abstract][Full Text] [Related]
12. Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.
Suzuki H; Sezaki H; Suzuki F; Kasuya K; Sano T; Fujiyama S; Kawamura Y; Hosaka T; Akuta N; Saitoh S; Kobayashi M; Arase Y; Ikeda K; Suzuki Y; Kumada H
Hepatol Res; 2019 Dec; 49(12):1406-1413. PubMed ID: 31347756
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
15. Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy.
Idalsoaga F; Robles C; Ortiz A; Corsi O; Fuentes-López E; Díaz LA; Ayares G; Arrese M; Arab JP
Therap Adv Gastroenterol; 2024; 17():17562848241254267. PubMed ID: 38812703
[TBL] [Abstract][Full Text] [Related]
16. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
[TBL] [Abstract][Full Text] [Related]
17. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
Glal KAM; Abd-Elsalam SM; Mostafa TM
J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.
Flamm SL
Therap Adv Gastroenterol; 2011 May; 4(3):199-206. PubMed ID: 21694804
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial.
Suzuki K; Endo R; Takikawa Y; Moriyasu F; Aoyagi Y; Moriwaki H; Terai S; Sakaida I; Sakai Y; Nishiguchi S; Ishikawa T; Takagi H; Naganuma A; Genda T; Ichida T; Takaguchi K; Miyazawa K; Okita K
Hepatol Res; 2018 May; 48(6):411-423. PubMed ID: 29235218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
